复发难治-话题@MedSci

#复发难治#

49篇内容 | 844人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2046457, encodeId=de93204645e08, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, objectType=article, longId=299159, objectId=5c4f2991594a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c4f2991594a, replyNumber=0, likeNumber=35, createdTime=2022-10-14, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c4f2991594a, moduleTitle=LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c4f2991594a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046453, encodeId=faf32046453d4, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, objectType=article, longId=204326, objectId=d24d20432640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d24d20432640, replyNumber=0, likeNumber=42, createdTime=2021-03-20, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d24d20432640, moduleTitle=ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d24d20432640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046450, encodeId=24052046450b4, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, objectType=article, longId=201729, objectId=c1e7201e2955, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e7201e2955, replyNumber=0, likeNumber=53, createdTime=2021-02-13, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e7201e2955, moduleTitle=IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e7201e2955)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046452, encodeId=62b92046452b3, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, objectType=article, longId=204234, objectId=b3d02042345e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3d02042345e, replyNumber=0, likeNumber=49, createdTime=2021-05-09, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3d02042345e, moduleTitle=Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3d02042345e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046455, encodeId=34d1204645573, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=49, createdTime=2021-09-05, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046451, encodeId=23d12046451a6, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）, objectType=article, longId=203075, objectId=8c062030e5cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c062030e5cf, replyNumber=0, likeNumber=33, createdTime=2021-08-08, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c062030e5cf, moduleTitle=ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c062030e5cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046449, encodeId=5c24204644998, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, objectType=article, longId=200687, objectId=397520068ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397520068ed0, replyNumber=0, likeNumber=49, createdTime=2021-01-22, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397520068ed0, moduleTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397520068ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046454, encodeId=4fa72046454a8, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=瑞顺生物：国内治疗复发难治急性髓系白血病的异体DNT细胞药获批临床, objectType=article, longId=205881, objectId=ce2120588141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce2120588141, replyNumber=0, likeNumber=40, createdTime=2021-08-14, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce2120588141, moduleTitle=瑞顺生物：国内治疗复发难治急性髓系白血病的异体DNT细胞药获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce2120588141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046448, encodeId=82a2204644816, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, objectType=article, longId=198654, objectId=e12d1986548a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12d1986548a, replyNumber=0, likeNumber=38, createdTime=2020-12-23, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12d1986548a, moduleTitle=FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12d1986548a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046456, encodeId=c6892046456a3, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤, objectType=article, longId=207782, objectId=e4ee20e782e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4ee20e782e9, replyNumber=0, likeNumber=36, createdTime=2021-12-11, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4ee20e782e9, moduleTitle=FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4ee20e782e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046447, encodeId=e289204644e94, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=38, createdTime=2020-10-28, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046445, encodeId=42982046445cd, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, objectType=article, longId=196009, objectId=77a7196009ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a7196009ec, replyNumber=0, likeNumber=46, createdTime=2021-03-17, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a7196009ec, moduleTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a7196009ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046446, encodeId=094b2046446c9, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=43, createdTime=2020-12-07, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046440, encodeId=6fe92046440a9, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, objectType=article, longId=186916, objectId=68271869169f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68271869169f, replyNumber=0, likeNumber=43, createdTime=2020-02-20, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68271869169f, moduleTitle=Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68271869169f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046436, encodeId=42e5204643644, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=复发难治套细胞淋巴瘤MCL治疗安全有效, objectType=article, longId=184344, objectId=004a184344b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=004a184344b5, replyNumber=0, likeNumber=50, createdTime=2020-10-17, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=004a184344b5, moduleTitle=复发难治套细胞淋巴瘤MCL治疗安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=004a184344b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046433, encodeId=26902046433e7, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明, objectType=article, longId=179542, objectId=51df1e9542ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51df1e9542ae, replyNumber=0, likeNumber=34, createdTime=2020-07-21, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51df1e9542ae, moduleTitle=2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51df1e9542ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046438, encodeId=df07204643886, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, objectType=article, longId=184567, objectId=14fb18456e61, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14fb18456e61, replyNumber=0, likeNumber=49, createdTime=2020-03-17, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14fb18456e61, moduleTitle=DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14fb18456e61)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046444, encodeId=f8842046444eb, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA, objectType=article, longId=195152, objectId=4ee01951523a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ee01951523a, replyNumber=0, likeNumber=58, createdTime=2021-04-27, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ee01951523a, moduleTitle=复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ee01951523a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046439, encodeId=822d2046439f6, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, objectType=article, longId=186206, objectId=9fb1186206ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fb1186206ed, replyNumber=0, likeNumber=48, createdTime=2020-07-07, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fb1186206ed, moduleTitle=林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fb1186206ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2046437, encodeId=f8fe204643eb6, content=<a href='/topic/show?id=830c4258913' target=_blank style='color:#2F92EE;'>#复发难治#</a>, objectTitle=具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择, objectType=article, longId=184372, objectId=a2ac1843e2f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2ac1843e2f7, replyNumber=0, likeNumber=29, createdTime=2020-10-04, rootId=0, userName=luoxiaog, userId=02f5179, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2ac1843e2f7, moduleTitle=具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2ac1843e2f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

复发难治

2020-05-29

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

LEUKEMIA：Erk1/2i 和 CDK4/6i 联合治疗复发难治性多发性骨髓瘤

2022-10-14

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

ASH 2020：礼来的LOXO-305在复发难治CLL/SLL中显示62％的缓解率

2021-03-20

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

IMGN632治疗复发难治囊性浆细胞样树突状细胞肿瘤：FDA授予突破性疗法称号

2021-02-13

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

Br J Haematol：来那度胺治疗失败后，复发难治性多发性骨髓瘤可选择泊马度胺加低剂量地塞米松治疗

2021-05-09

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-09-05

医者仁心 (审核中...)

前往app查看评论内容

#复发难治#

ASH 2020：研究性新药Alvocidib治疗复发难治急性髓细胞白血病（AML）

2021-08-08

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药

2021-01-22

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

瑞顺生物：国内治疗复发难治急性髓系白血病的异体DNT细胞药获批临床

2021-08-14

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

FDA批准Monjuvi（tafasitamab-cxix）联合来那度胺治疗复发难治弥漫性大B细胞淋巴瘤

2020-12-23

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

FDA批准PEPAXTO（美法仑氟苯甲酰胺）用于治疗复发难治多发性骨髓瘤

2021-12-11

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2020-10-28

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效

2021-03-17

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2020-12-07

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

Hyleukin-7（NT-I7）联合Pembrolizumab治疗复发难治晚期实体瘤：美国FDA已批准IND申请

2020-02-20

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

复发难治套细胞淋巴瘤MCL治疗安全有效

2020-10-17

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

2019年SOHO：Venetoclax联合Navitoclax治疗复发难治ALL和淋巴母细胞淋巴瘤前景光明

2020-07-21

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

DARZALEX（Daratumumab）方案显著增加复发难治多发性骨髓瘤患者的PFS

2020-03-17

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

复发难治肾细胞癌的治疗或迎新突破：FDA已批准Tivozanib的NDA

2021-04-27

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

林桐榆教授：复发难治弥漫大B细胞淋巴瘤治疗关键与挑战

2020-07-07

luoxiaog (审核中...)

前往app查看评论内容

#复发难治#

具备更好的靶选择性，ORR超过88%！复发难治慢性淋巴细胞白血病/小细胞淋巴瘤带来治疗新选择

2020-10-04

科室
- - 订阅+
  - 更多科室
工具
服务